Fundraise
Donate
Home/Industry/MavriX Bio Receives FDA Fast Track Designation for MVX-220 for Treatment of Angelman Syndrome

MavriX Bio Receives FDA Fast Track Designation for MVX-220 for Treatment of Angelman Syndrome

Read the press release

Related News

  • Industry

Oct 8, 2026: Ultragenyx Community Webinar

On October 8, 2026, ASF and FAST hosted a webinar with Ultragenyx after the announcement that their phase 3 trial for GTX-102 (aspire) did not meet primary or key secondary

  • Industry

MavriX Bio Announces FDA Rare Pediatric Disease Designation for Investigational MVX-220 for the Treatment of Angelman Syndrome

Read the press release

  • Industry

Skylark Bio Expands Pipeline with First CNS Development Program, SKY-AS, Targeting UBE3A Restoration in Angelman Syndrome

Read press release

  • Industry

GTX-102 Phase 3 Results: What We Know, What We’re Still Learning, and Next Steps

FAST's CSO, Allyson Berent, addresses the Aspire trial results in a candid letter, exploring what the data mean, what questions remain, and how the community will move forward together.
  • Industry

Ultragenyx shares that GTX-102 trials will officially close on Oct 30, 2026.

Read the letter from Ultragenyx to the community: Angelman-Syndrome-Community-Update-9.16

  • Industry

Ionis Pharmaceuticals: A letter to the Angelman syndrome community.

Ionis addresses community questions following the ASPIRE trial results, reaffirming its commitment to obudanersen (ION582) through the HALOS, REVEAL, and CHAMPION trials
View More News

What are you looking for?

Find information on Angelman syndrome, research, clinical trials, resources, and ways to get involved.